At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,002 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Insulin Glargine for Type 2 Diabetes Mellitus. Completed, enrolled 2,002 participants across 216 sites in 15 countries.
Detailed Summary
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesArgentina, Australia, Brazil, Canada, Greece, Israel, Mexico, Poland, Puerto Rico, Romania, Russia, Slovakia, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartNov 2018
Primary CompletionJan 2021
Study CompletionApr 2021
TodayJul 2026
First PostedNov 5, 2018
Enrollment StartNov 20, 2018
Primary CompletionJan 22, 2021
Study CompletionApr 22, 2021
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 7.7 years ago
Interventions
Tirzepatidedrug
Administered SC.
Insulin Glarginedrug
Administered SC